Aura Biosciences (AURA) officer receives RSU and option grants

Q: How many Aura Biosciences (AURA) RSUs were granted to Anthony S. Gibney?

Anthony S. Gibney was granted 71,245 restricted stock units of Aura Biosciences common stock. Each RSU represents one share, vesting in four substantially equal annual installments starting on January 15, 2027 , provided he remains in service on each vesting date.

Q: What are the terms of the Aura Biosciences (AURA) stock option granted to Anthony S. Gibney?

Aura Biosciences granted Anthony S. Gibney a stock option for 128,755 shares . 25% of the underlying shares vest on February 1, 2027 , with the remainder vesting pro rata in 36 monthly installments , subject to his continued service.

Q: Are Anthony S. Gibney’s new Aura Biosciences (AURA) equity awards immediately vested?

No, the awards are not immediately vested. The 71,245 RSUs vest in four annual installments beginning January 15, 2027 , and the 128,755-share stock option vests 25% on February 1, 2027 with the balance vesting monthly thereafter.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Gibney Anthony S reported acquisition or exercise transactions in this Form 4 filing.

Aura Biosciences, Inc. reported that company officer Anthony S. Gibney received new equity awards. On March 2, 2026, he was granted 71,245 shares of common stock through a restricted stock unit award and a stock option for 128,755 shares.

The restricted stock units vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on his continued service. The stock option vests with 25% of the shares on February 1, 2027, and the remaining shares vest pro rata in 36 monthly installments, also subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gibney Anthony S

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	128,755	$0.00	--
Grant/Award	Common Stock	71,245	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 128,755 shares (Direct); Common Stock — 278,178 shares (Direct)

Footnotes (1)

These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 04:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gibney Anthony S

(Last)

(First)

(Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON

02135

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		A		71,245⁽¹⁾	A	$0	278,178	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$6.14	03/02/2026		A		128,755		⁽²⁾	03/02/2036	Common Stock	128,755	$0	128,755	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

2. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

Chief Financial and Business Officer

	/s/ Conor Kilroy, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Aura Biosciences (AURA) report for Anthony S. Gibney?

Aura Biosciences reported that officer Anthony S. Gibney received equity awards. He was granted a restricted stock unit award for 71,245 common shares and a stock option for 128,755 shares on March 2, 2026, both tied to continued service.

How many Aura Biosciences (AURA) RSUs were granted to Anthony S. Gibney?

Anthony S. Gibney was granted 71,245 restricted stock units of Aura Biosciences common stock. Each RSU represents one share, vesting in four substantially equal annual installments starting on January 15, 2027, provided he remains in service on each vesting date.

What are the terms of the Aura Biosciences (AURA) stock option granted to Anthony S. Gibney?

Aura Biosciences granted Anthony S. Gibney a stock option for 128,755 shares. 25% of the underlying shares vest on February 1, 2027, with the remainder vesting pro rata in 36 monthly installments, subject to his continued service.

Are Anthony S. Gibney’s new Aura Biosciences (AURA) equity awards immediately vested?

No, the awards are not immediately vested. The 71,245 RSUs vest in four annual installments beginning January 15, 2027, and the 128,755-share stock option vests 25% on February 1, 2027 with the balance vesting monthly thereafter.

Under which plan were Aura Biosciences (AURA) RSUs granted to Anthony S. Gibney?

The restricted stock unit award to Anthony S. Gibney was granted under Aura Biosciences’ 2021 Stock Option and Incentive Plan. Each RSU corresponds to one share of common stock, with vesting based on his continued service over multiple years.

Did the Aura Biosciences (AURA) Form 4 show any stock sales by Anthony S. Gibney?

No stock sales were reported for Anthony S. Gibney in this Form 4. The filing only shows acquisitions via equity awards: a restricted stock unit grant for 71,245 shares and a stock option grant for 128,755 shares, both with future vesting schedules.